Heidelberg Pharma AG (WL6)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Heidelberg Pharma AG (WL6) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012203
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Heidelberg Pharma AG(Heidelberg Pharma) formerly known as Wilex AG is a biopharmaceutical company with a focus on cancer. The company develops therapeutic and diagnostic product candidates for the treatment and specific detection of various cancers. It develops products based on and small molecules and antibodies, which are offered for out-licensing. Wilex’s pipeline products are focused at treating multiple myeloma, prostate cancer, hematological cancers, metastatic pancreatic cancers, leukemia, non- metastatic ccRCC, kidney cancers and solid tumors. Heidelberg Pharma GmbH (Heidelberg), Wilex’s subsidiary provides preclinical contract research services and an antibody drug conjugate (ADC) technology platform. Heidelberg focuses on the development of a proprietary ADC technology. Heidelberg Pharma is headquartered in Munich, Germany.

Heidelberg Pharma AG (WL6) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Heidelberg Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Telix Pharma Enters into Licensing Agreement with Wilex 12
Heidelberg Pharma Enters into Research Agreement with Takeda Pharma 13
Nordic Nanovector Enters into Research Agreement with Heidelberg Pharma 14
Heidelberg Pharma Enters into Agreement with Celonic 15
Advanced Proteome Therapeutics Enters into Agreement with Heidelberg Pharma 16
MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 17
Licensing Agreements 18
Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 18
RedHill Biopharma Enters into Licensing Agreement with Wilex for Mesupron 19
Wilex Enters Into Licensing Agreement With Link Health For Mesupron 20
Heidelberg Pharma Enters Into Licensing Agreement With Roche For Antibody Targeted Amanitin Conjugates 21
WILEX Enters Into Licensing Agreement With Prometheus Labs For RENCAREX 22
Equity Offering 23
Heidelberg Pharma Raises USD22.8 Million in Rights Offering of Shares 23
Wilex Raises USD5.4 Million in Rights Offering of Shares 24
Wilex to Raise USD4.7 Million in Rights Offering of Shares 25
Wilex Raises USD1.81 Million in Private Placement of Shares 27
Wilex Raises USD0.86 Million in Rights Offering of Shares 28
Wilex Raises USD4.4 Million in Right Issue of Shares 29
Wilex Completes Private Placement Of Shares For US$12.4 Million 30
Wilex Completes Rights Offering Of Shares For US$7.8 Million 31
Wilex Completes Rights Offering Of Shares For US$12.6 Million 32
Debt Offering 33
Heidelberg Pharma Raises USD17.5 Million in Private Placement of Bonds 33
Asset Transactions 34
UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 34
Acquisition 35
WILEX Acquires Heidelberg Pharma For US$26.8 Million 35
Heidelberg Pharma AG – Key Competitors 37
Heidelberg Pharma AG – Key Employees 38
Heidelberg Pharma AG – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Jul 13, 2017: WILEX reports on first half-year 40
Apr 12, 2017: WILEX: Interim management statement on the first three months of 2017 42
Mar 30, 2017: WILEX announces financial figures for the 2016 fiscal year and reports on course of business 44
Jul 14, 2016: WILEX publishes Half-yearly Financial Report 46
Apr 14, 2016: WILEX AG: Interim management statement on the first quarter of 2016 48
Mar 22, 2016: WILEX announces financial figures for the 2015 financial year and reports on course of business 51
Corporate Communications 53
Jun 02, 2016: WILEX announces change on the Executive Management Board 53
Apr 06, 2016: WILEX plans change on the Supervisory Board 54
Product News 55
03/01/2016: RedHill Biopharma Provides Update on MESUPRON 55
Product Approvals 56
Jan 13, 2016: WILEX’s partner Link Health submits IND application for clinical Phase I with the uPA inhibitor MESUPRON in China 56
Other Significant Developments 57
Oct 13, 2016: WILEX: Interim Management Statement on the First Nine Months of 2016 57
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Heidelberg Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Heidelberg Pharma AG, Deals By Therapy Area, 2011 to YTD 2017 9
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Telix Pharma Enters into Licensing Agreement with Wilex 12
Heidelberg Pharma Enters into Research Agreement with Takeda Pharma 13
Nordic Nanovector Enters into Research Agreement with Heidelberg Pharma 14
Heidelberg Pharma Enters into Agreement with Celonic 15
Advanced Proteome Therapeutics Enters into Agreement with Heidelberg Pharma 16
MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 17
Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 18
RedHill Biopharma Enters into Licensing Agreement with Wilex for Mesupron 19
Wilex Enters Into Licensing Agreement With Link Health For Mesupron 20
Heidelberg Pharma Enters Into Licensing Agreement With Roche For Antibody Targeted Amanitin Conjugates 21
WILEX Enters Into Licensing Agreement With Prometheus Labs For RENCAREX 22
Heidelberg Pharma Raises USD22.8 Million in Rights Offering of Shares 23
Wilex Raises USD5.4 Million in Rights Offering of Shares 24
Wilex to Raise USD4.7 Million in Rights Offering of Shares 25
Wilex Raises USD1.81 Million in Private Placement of Shares 27
Wilex Raises USD0.86 Million in Rights Offering of Shares 28
Wilex Raises USD4.4 Million in Right Issue of Shares 29
Wilex Completes Private Placement Of Shares For US$12.4 Million 30
Wilex Completes Rights Offering Of Shares For US$7.8 Million 31
Wilex Completes Rights Offering Of Shares For US$12.6 Million 32
Heidelberg Pharma Raises USD17.5 Million in Private Placement of Bonds 33
UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 34
WILEX Acquires Heidelberg Pharma For US$26.8 Million 35
Heidelberg Pharma AG, Key Competitors 37
Heidelberg Pharma AG, Key Employees 38
Heidelberg Pharma AG, Subsidiaries 39

★海外企業調査レポート[Heidelberg Pharma AG (WL6)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bachmann electronic GmbH:企業の戦略的SWOT分析
    Bachmann electronic GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Zebra Technologies Corporation:企業の戦略・SWOT・財務情報
    Zebra Technologies Corporation - Strategy, SWOT and Corporate Finance Report Summary Zebra Technologies Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Flex Ltd (FLEX):医療機器:M&Aディール及び事業提携情報
    Summary Flex Ltd (Flex) provides design, engineering, manufacturing, and supply chain services to electronics original equipment manufacturers. The company, through its Sketch-to-Scale concept, provides concept design, prototype creation, intellectual property protection, new product introduction, a …
  • Transelectrica SA:企業の発電所・SWOT分析2018
    Transelectrica SA - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees ( …
  • Theravectys SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Theravectys SA (TheraVectys) is a clinical development biotech company that develops new generation therapeutic vaccines and immunotherapies. The company develops viral vectors vaccines to support body and prepare against future infections by pre-exposing immune system to partial, dead, inac …
  • Upsher-Smith Laboratories Inc:企業のM&A・事業提携・投資動向
    Upsher-Smith Laboratories Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Upsher-Smith Laboratories Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • EPAM Systems Inc (EPAM):企業の財務・戦略的SWOT分析
    EPAM Systems Inc (EPAM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • TechnipFMC Plc (FTI):石油・ガス:M&Aディール及び事業提携情報
    Summary TechnipFMC plc (TechnipFMC) is a provider of oil and gas technologies, systems and services. The company focuses on subsea, surface technologies, onshore and offshore projects. Its portfolio of subsea services include drilling, asset management, installation of oil and gas field, remotely op …
  • Bryte Insurance Company Ltd:企業の戦略・SWOT・財務情報
    Bryte Insurance Company Ltd - Strategy, SWOT and Corporate Finance Report Summary Bryte Insurance Company Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Bitauto Holdings Limited:企業のM&A・事業提携・投資動向
    Bitauto Holdings Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bitauto Holdings Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Sinclair Broadcast Group Inc (SBGI):企業の財務・戦略的SWOT分析
    Summary Sinclair Broadcast Group Inc (Sinclair) is a television broadcasting service provider that owns and operates television programs. The company's service portfolio includes content creation, distribution platforms, advertising platform and technical solutions. It offers content across various …
  • Zion Oil & Gas Inc (ZN):企業の財務・戦略的SWOT分析
    Summary Zion Oil & Gas Inc (Zion Oil) is an oil and gas company that explores and produces oil and gas properties in Israel. The company offers services such as geophysical, geological, and other science-based studies and surveys to support oil and gas exploration and development services. It holds …
  • Mitsubishi Ufj Financial Group Inc:企業の戦略・SWOT・財務分析
    Mitsubishi Ufj Financial Group Inc - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Ufj Financial Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • The Credit Mutuel-Cic Group
    The Credit Mutuel-Cic Group - Strategy, SWOT and Corporate Finance Report Summary The Credit Mutuel-Cic Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • China Petroleum & Chemical Corp (600028):電力:M&Aディール及び事業提携情報
    Summary China Petroleum & Chemical Corp (Sinopec Corp), a subsidiary of China Petrochemical Corporation, is a vertically integrated energy and chemical company. It is involved in the oil and gas exploration and production, extraction, pipeline transmission and marketing; oil refining; and production …
  • Coca-Cola FEMSA SAB de CV:企業の戦略・SWOT・財務情報
    Coca-Cola FEMSA SAB de CV - Strategy, SWOT and Corporate Finance Report Summary Coca-Cola FEMSA SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • ViaSat Inc:企業の戦略・SWOT・財務情報
    ViaSat Inc - Strategy, SWOT and Corporate Finance Report Summary ViaSat Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • INEOS Olefins & Polymers Europe:企業の戦略的SWOT分析
    INEOS Olefins & Polymers Europe - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Qualcomm Incorporated (QCOM):医療機器:M&Aディール及び事業提携情報
    Summary Qualcomm Incorporated (Qualcomm) is a technology and communication company. The company designs and manufactures digital wireless telecommunications products and services. Qualcomm offers integrated circuits and system software for wireless mobile devices. The major technologies such as code …
  • Deluxe Corporation:企業の戦略・SWOT・財務分析
    Deluxe Corporation - Strategy, SWOT and Corporate Finance Report Summary Deluxe Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆